R
Rachel Brough
Researcher at Institute of Cancer Research
Publications - 54
Citations - 6254
Rachel Brough is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: PARP inhibitor & Synthetic lethality. The author has an hindex of 29, co-authored 46 publications receiving 5096 citations. Previous affiliations of Rachel Brough include Breast Cancer Now.
Papers
More filters
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal ArticleDOI
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards,Rachel Brough,Christopher J. Lord,Rachael Natrajan,Radost Vatcheva,Douglas A. Levine,Jeff Boyd,Jorge S. Reis-Filho,Alan Ashworth +8 more
TL;DR: It is shown that resistance to PARP inhibition can be acquired by deletion of a mutation in BRCA2, and new BRCa2 isoforms were expressed in the resistant lines as a result of intragenic deletion of the c.6174delT mutation and restoration of the open reading frame (ORF).
Journal ArticleDOI
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
Ana M. Mendes-Pereira,Sarah A. Martin,Rachel Brough,Afshan McCarthy,Jessica R. Taylor,Jung-Sik Kim,Todd Waldman,Christopher J. Lord,Alan Ashworth +8 more
TL;DR: The data presented here now suggests that the clinical assessment of PARP inhibitors should be extended beyond those with BRCA mutations to a larger group of patients with PTEN mutant tumours.
Journal ArticleDOI
The Shieldin complex mediates 53BP1-dependent DNA repair
Sylvie M. Noordermeer,Sylvie M. Noordermeer,Salomé Adam,Dheva Setiaputra,Marco Barazas,Stephen J. Pettitt,Alexanda K. Ling,Michele Olivieri,Michele Olivieri,Alejandro Álvarez-Quilón,Nathalie Moatti,Michal Zimmermann,Stefano Annunziato,Dragomir B. Krastev,Feifei Song,Inger Brandsma,Jessica Frankum,Rachel Brough,Alana Sherker,Alana Sherker,Sébastien Landry,Rachel K. Szilard,Meagan Munro,Andrea McEwan,Theo Goullet de Rugy,Zhen-Yuan Lin,Traver Hart,Jason Moffat,Anne-Claude Gingras,Anne-Claude Gingras,Alberto Martin,Haico van Attikum,Jos Jonkers,Christopher J. Lord,Sven Rottenberg,Sven Rottenberg,Daniel Durocher,Daniel Durocher +37 more
TL;DR: The 53 BP1 effector complex shieldin is involved in non-homologous end-joining and immunoglobulin class switching, and acts to protect DNA ends to facilitate the repair of DNA by 53BP1, it is shown that binding of single-stranded DNA by SHLD2 is critical for shieldin function.
Journal ArticleDOI
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner,Christopher J. Lord,Elizabeth Iorns,Rachel Brough,Sally Swift,Richard Elliott,Sydonia Rayter,Andrew Tutt,Andrew Tutt,Alan Ashworth +9 more
TL;DR: It is shown that CDK5 is required in non‐neuronal cells for the DNA‐damage response and, in particular, intra‐S and G2/M cell‐cycle checkpoints, which highlights the potential of synthetic lethal siRNA screens with chemical inhibitors to define new determinants of sensitivity and potential therapeutic targets.